Filing Details

Accession Number:
0001645113-22-000017
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-03-07 18:18:57
Reporting Period:
2022-03-03
Accepted Time:
2022-03-07 18:18:57
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1645113 Novocure Ltd NVCR () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1632237 Ely Benaim C/O Novocure Inc.,
20 Valley Stream Parkway, Suite 300
Malvern PA 19355
Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Acquisiton 2022-03-03 17,371 $0.00 45,570 No 4 A Direct
Ordinary Shares Disposition 2022-03-03 803 $74.50 44,767 No 4 S Direct
Ordinary Shares Disposition 2022-03-04 1,510 $70.41 43,257 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Ordinary Shares Options to Buy Ordinary Shares Acquisiton 2022-03-03 30,422 $80.59 30,422 $80.59
Ordinary Shares Options to Buy Ordinary Shares Acquisiton 2022-03-03 5,452 $80.59 5,452 $80.59
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
30,422 2023-03-01 2032-02-29 No 4 A Direct
5,452 2023-03-01 2032-02-29 No 4 A Direct
Footnotes
  1. Represents restricted share units that are scheduled to vest in equal installments on March 1, 2023, 2024 and 2025, subject to the reporting person's continued employment through such dates.
  2. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
  3. Options to buy 30,422 ordinary shares will vest and become exercisable in equal installments on each of March 1, 2023, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates.
  4. Options to buy 5,452 ordinary shares will vest and become exercisable in equal installments on each of March 1, 2023 and 2024, subject to the reporting person's continued employment through such dates.